BarbaraBurtnessMD

PubMed

• Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.
  Sujith Baliga, Ahmad K Abou-Foul, Pablo Parente, Petr Szturz, Juliette Thariat, Aditya Shreenivas, Paul Nankivell, Federica Bertolini, Julian Biau, Dukagjin Blakaj, Si...> ;European Journal of Cancer. 2024 Mar 30
• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head ...
  Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Poin...> ;The Lancet. Oncology. 2024 Mar 29
• An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
  Myrto Moutafi, Yalai Bai, Thazin Nwe Aung, Sneha Burela, Matthew Liu, Fahad Shabbir Ahmed, Bryant Schultz, Denise C Connolly, Amanda Psyrri, Vasiliki Xirou, Randall J ...> ;Oral Oncology. 2024 Mar 27
• Impact ofF-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
  Stefan P Haider, Tal Zeevi, Kariem Sharaf, Moritz Gross, Martin Canis, Christoph A Reichel, Philipp Baumeister, Amit Mahajan, Benjamin H Kann, Benjamin L Judson, Manju...> ;Journal of Nuclear Medicine. 2024 Mar 21
• The role of surgery and deescalation for HPV-related oropharyngeal cancer.
  Kevin J Contrera, Mihir R Patel, Robert L Ferris, Barbara Burtness, Ranee Mehra> ;Cancer. 2024 Mar 18
• Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
  Brahmer, J., Long, G., Hamid, O., Garon, E., Herbst, R., Andre, T., Armand, P., Bajorin, D., Bellmunt, J., Burtness, B., Choueiri, T., Cohen, E., Diaz, L., Shitara, K....> ;European Journal of Cancer. 2024 Mar 1
• A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.
  Flamand, Y., Johnson, J., Vathiotis, I., Levine, M., Li, S., Argiris, A., Savvides, P., Forastiere, A., Burtness, B.> ;European Journal of Cancer. 2024 Mar 1
• Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.
  Lozar, T., Wang, W., Gavrielatou, N., Christensen, L., Lambert, P., Grasic Kuhar, C., Harari, P., Rimm, D., Burtness, B., Carchman, E.> ;Viruses. 2023 Nov 25
• Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.
  Stuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, George Shenouda, Jeffrey M Bumpous, Robert E Wallace, Christine H Chung, Adel K El-Naggar, Clement K Gwede, Barba...> ;JAMA Oncology. 2023 Nov 1
• 1 citations
  Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.
  Tasoulas, J., Tasoulas, J., Travis P Schrank, Aditi Kothari, William H Weir, Wesley H Stepp, Hina Rehmani, Xinyi Liu, Xiaowei Wang, Andrew Sewell, Xue Li, Jason Tasoul...> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Aug 8
• 1 citations
  Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
  Julie E Bauman, Nabil F Saba, Denise Roe, Jessica R Bauman, John Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly, Audrey Baker, C...> ;Journal of Clinical Oncology. 2023 Aug 1
• 1 citations
  The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.
  Rebecca A Snyder, Barbara Burtness, May Cho, Jaydira Del Rivero, Deborah B Doroshow, Kathryn E Hitchcock, Aparna Kalyan, Christina A Kim, Jelena Lukovic, Aparna R Pari...> ;Journal of the National Cancer Institute. 2023 Oct 9
• Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety...
  Annika Belzer, Jolanta Pach, Ryland D Mortlock, James Clune, Kelly Olino, Mario Sznol, Aarti Bhatia, Barbara Burtness, Sean Christensen, Jonathan S Leventhal> ;JAAD International. 2023 Jun 1
• 1 citations
  Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.
  Qian, D., Ulrich, B., Peng, G., Zhao, H., Conneely, K., Miller, A., Bruner, D., Eldridge, R., Wommack, E., Higgins, K., Shin, D., Saba, N., Smith, A., Burtness, B., Pa...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Apr 1
• 2 citations
  Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.
  Niki Gavrielatou, Ioannis Vathiotis, Thazin Nwe Aung, Saba Shafi, Sneha Burela, Aileen I Fernandez, Myrto Moutafi, Barbara Burtness, Panagiota Economopoulou, Maria Ana...> ;Cancer Research Communications. 2023 Apr 1
• 1 citations
  First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
  Barbara Burtness> ;Journal of Clinical Oncology. 2023 Apr 20
• Top advances of the year: Head and neck cancer.
  Avanti Verma, Barbara Burtness> ;Cancer. 2023 May 1
• 6 citations
  Author Correction: Head and neck squamous cell carcinoma.
  Daniel E Johnson, Barbara Burtness, C René Leemans, Vivian Wai Yan Lui, Julie E Bauman, Jennifer R Grandis> ;Nature Reviews. Disease Primers. 2023 Jan 19
• 20 citations
  Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
  Aarti Bhatia, Barbara Burtness> ;Drugs. 2023 Feb 1
• Methodologic Concerns in Secondary Analysis of KEYNOTE-048.
  Barbara Burtness, Jianxin Lin, Denis Souliéres> ;JAMA Oncology. 2022 Dec 1
• 54 citations
  Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
  Kevin J Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Basté, Prakash Neupane, Ås...> ;Journal of Clinical Oncology. 2023 Feb 1
• 1 citations
  Integrating Targeted Therapies in the Management of Head and Neck Cancers.
  Barbara Burtness> ;Cancer Journal. 2022 Sep 27
• 1 citations
  Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
  Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Gallow...> ;Journal of the National Cancer Institute. 2022 Dec 8
• 2 citations
  Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a f...
  Rebecca Forman, Hari Deshpande, Barbara Burtness, Aarti K Bhatia> ;Head & Neck. 2022 Aug 1
• 13 citations
  Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
  Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W Bowles, Hyunseok Kang, Barbara Burtness, Eric ...> ;Journal of Clinical Oncology. 2022 Dec 20
• Join now to see all

Journal Articles

• HPV Status in Unknown Primary Head and Neck Cancer: Prognosis and Treatment Outcomes  
  Shayan Cheraghlou, Sina J Torabi, Michael D Otremba, Barbara A Burtness, Saral Mehra, Benjamin L Judson, Wendell G Yarbrough, The Laryngoscope
• Images in Medicine: Cetuximab-associated acneiform rash.  
  Moss J and B Burtness, N Engl J Med 353:e17.
• Oxaliplatin induces a delayed immune hemolytic anemia: A case report and review of the literature.  
  Noronha V, B Burtness, J Murren, TP Duffy., Clin Colorectal Ca 5:283-286
• Bimodal population or pathologist artifact? Correspondence.  
  4. Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B, J Clin Oncol; 25:2487-8.
• Oropharyngeal squamous cell carcinoma treatment: current standards and future directions  
  Marur S and Burtness B, Curr Opinion Oncol, 5/1/2014
• Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC)  
  Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A, PLos One, 1/1/2014
• Dysplasia at the margin? Investigating the case for subsequent therapy in 'Low-Risk' squamous cell carcinoma of the oral tongue  
  Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ, Oral Oncol, 11/1/2013
• Quantification of excision repair cross complementing group 1 (ERCC1) and survival in p16-negative squamous cell head and neck cancers  
  Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova A, Golemis EA, Flieder DB, Cooper H, Lango MN, Ridge JA, Burtness B, Clin Cancer Res, 10/2/2013
• p16 status, pathologic and clinical characteristics, biomolecular signature, and long term outcomes in unknown primary carcinomas of the head and neck  
  Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA, Head Neck, 10/1/2013
• Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer  
  Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS, J Gastrointest Surg, 9/4/2013
• Head and Neck Cancers, Version 22013  
  Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL J..., J Natl Compr Canc Netw, 8/1/2013
• Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation  
  Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, ..., Cancer Discov, 1/1/2013
• Aurora kinases in head and neck cancer  
  Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA, Lancet Oncol, 1/1/2013
• Novel Targets in HPV-Negative Head and Neck Cancer-Overcoming Resistance to EGFR Inhibition  
  Burtness B, Bauman JE, Galloway T, Lancet Oncol, 1/1/2013
• Esophageal carcinoma: are modern targeted therapies shaking the rock?  
  Boland PM and Burtness B, Curr Opinion Oncol, 1/1/2013
• Unilateral Neck Therapy in the Human Papillomavirus-Era: Virus Association does not Alter Accepted Regional Spread Patterns  
  Galloway T, Lango M, Burtness B, Mehra R, Ruth K, Ridge J, Head and Neck, 1/1/2012
• Psychological Functioning of Caregivers for Head and Neck Cancer Patients  
  Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY, Oral Oncology, 1/1/2012
• A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer A Fox Chase Extramural ...  
  Dotan E, Meropol NJ, Burtness B, Denlinger C, Lee J, Mintzer D, Zambito F, Zhu F, Qi K, Tuttle H, Sylvester J, Astsaturov I, Cohen SJ, Journal of Gastrointestinal Cancer, 1/1/2012
• Informational needs of head and neck cancer patients  
  Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA, Health and Technology, 1/1/2012
• Nuclear and Cytoplasmic Epidermal Growth Factor Receptor and p16 expression in Head and Neck Squamous Cell Carcinoma  
  Husain H, Psyrri A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Ross DT, Burtness B, and Chung CH, Laryngoscope, 1/1/2012
• Comment on "Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling"  
  Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ, Sci Signal, 1/1/2012
• Multi-Modality Therapy for Cancer of the Esophagus and GE Junction  
  Tejani MA, Burtness BA, Curr Treat Options Oncol, 1/1/2012
• Significance of pathologic response to preoperative therapy in pancreatic cancer  
  Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP, Ann Surg Oncol, 12/1/2011
• Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-a...  
  Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ, Int J Radiat Oncol Biol Phys, 1/1/2011
• Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma  
  Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ, Am J Clin Oncol, 1/1/2011
• Join now to see all

Books/Book Chapters

• Novel targets in pancreatic cancer: focus on future paths to therapy. 
  Cohen S and B Burtness.
• Clinical use in colorectal cancer of monoclonal antibodies to the epidermal growth factor receptor. 
  Burtness B
• HER signaling in pancreatic cancer. 
  Burtness B
• Viruses in head and neck cancer: prevention and therapy. 
  Psyrri A and B BurtnessExpert Rev Anticancer Ther
• Molecular selection for 'smart' study design in lung cancer. 
  Chapter: Targeted therapies. 
  Psyrri A, Burtness BEditors: Nat Rev Clin Oncol. 7:621-2..
• Head and Neck Cancer. 
  Psyrri A, Burtness B, Harari PM, et al
• Oropharyngeal cancer. 
  26. Psyrri A, Prezas L, Burtness B.
• Andreoli’s and Carpenter’s Cecil Essentials of Medicine. 
  Chapter: Cancer biology and etiology. 
  Khorana AA and B Burtness.Edition 8th,
• Principles of Cancer Therapy 
  Chapter: Andreoli’s and Carpenter’s Cecil Essentials of Medicine 
  Khorana AA and B BurtnessEdition 8th,
• Targeting EGFR resistance networks in Head and Neck Cancer. 
  Chapter: Cell Signaling 
  29. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS
• Head and neck cancers. 
  30. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, K...J Natl Compr Canc Netw
• Bevacizumab and Erlotinib with Chemoradiation for Head and Neck Cancer. 
  Chapter: Commentary 
  Burtness B.
• Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. 
  Chapter: Drug Resist Updates 
  32. Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, and Golemis EA.
• NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated with EGFR Inhibition in Patients with Cancer. 
  Chapter: J Natl Compr Ca Network 
  Burtness B, M Anadkat, S Basti, M Hughes, ME Lacouture, JS McClure, PM Myskowski, J Paul, CS Perlis, L Saltz, S Spencer.
• Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 
  Faller B and B Burtness
• Antibody-based Therapies for Solid Tumors, in Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. 
  Shanbhag S and B BurtnessEditors: B Minev.Springer Science and Business Media, Dordrecht
• Head and neck cancer. 
  37. Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT
• Mucosal melanoma of the head and neck. 
  39. Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Ki...
• Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. 
  40. Tejani MA, Burtness BA.
• Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's Disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant. 
  Chapter: Bone Marrow Transplant 
  Seropian S, R Nadkarni, AP Jillella, E Salloum, GL Hu, B Burtness, D Zelterman, D Cooper
• Phase I studies of anti-epidermal growth factor receptor chimeric monoclonal antibody C225 alone and in combination with cisplatin. 
  Baselga J, D Pfister, MR Cooper, R Cohen, B Burtness, M Bos, G D'Andrea, A Seidman, L Norton, K Gunnett, J Falcey, V Anderson, H Waksal, J MendelsohnEditors: J Clin Oncol.
• The maximum negative binomial distribution. 
  Zhang Z, BA Burtness, D Zelterman.Editors: J Stat Planning Inference.
• Phase II evaluation of pre-operative chemoradiation and post- adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. 
  Heath EI, BA Burtness, RF Heitmiller, R Salem, L Kleinberg, J Knisely, SC Yang, MA Talamini, HS Kaufman, MI Canto, T-T Wu, K Olukayode, AA Forastiere.Editors: J Clin Oncol.
• The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. 
  Chapter: Bone Marrow Transplantation 
  15. Rose M, F Lee, A Gollerkeri, E D’Andrea, D Psyrri, T Bdolah-Abram, BA Burtness
• A phase I study of the antimetabolite (e)-2’-fluoromethylene-2’-deoxycytidine administered as a twice weekly infusion. 
  Burtness B, M Belker, M Stoltz, KM Peccerillo, LA Lamb, SE Chmael, A McKeon, MB Clark, J Winship, JC Marsh, G Pizzorno, VT DeVita Jr.Editors: Cancer J Sci Am.
• Join now to see all

Abstracts/Posters

• EGFR inhibition in head and neck cancer – more insights but more questions
  Forastiere AA and BA Burtness., J Clin Oncol 25:2152-5
• Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer.
  Shanbhag S and B Burtness, Eur J Clin Med Oncol
• A 5 year follow up of an expanded phase II study evaluating adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high-risk breast cancer.
  Abu-Khalaf M, S Windsor, K Ebisu, S Salikooti, G Chung, M DiGiovanna, B Haffty, M Abrams, L Farber, AD Hsu, M Reiss, D Zelterman, B Burtness., Oncology 69:372-383.
• Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor receptor, for the treatment of...
  Burtness BA, Y Li, M Goldwasser, W Flood, B Mattar, A Forastiere., J Clin Oncol
• Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  Bossuyt V, O Fadare, M Martel, B Burtness, R Camp, F Tavassoli., Int J Surg Pathol 13:319-327.
• Quantitative analysis of VEGF, Flt-1, and Flk-1 expression on a pancreatic cancer tissue microarray.
  GG Chung, HH Yoon, MP Zerkowski, DL Rimm, R Camp, M Harigopal, LA Charette, BA Burtness., Cancer; 106:1677-84.
• Discordance between breast magnetic resonance imaging and residual disease on pathology in responders to neoadjuvant chemotherapy for stage III breast
  Kwong M S, GC Chung, L J Horvath, D Carter, A G Hsu, B A Ward, B Haffty, F Tavassoli, B A Burtness., Cancer J 12:212-21.
• Discordance between breast magnetic resonance imaging and residual disease on pathology in responders to neoadjuvant chemotherapy for stage III breast cancer.
  Kwong M S, GC Chung, L J Horvath, D Carter, A G Hsu, B A Ward, B Haffty, F Tavassoli, B A Burtness., Cancer J 12:212-21.
• Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for hig...
  Abu-Khalaf M, Juneja V, Chung G, DiGiovanna M, Wackers F, Lee F. and Burtness B., Br Ca Treat Rep 104:341-9.
• Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer Cancer.
  Yu A, PM Weinberger, C Sasaki, BL Egleston, WF Speier IV, B Haffty, D Kowalski, R Camp, D Rimm, E Vairaktaris, B Burtness, A Psyrri., Cancer Epidemiol Biomarkers Prev; 16: 553-558.
• Automated image analysis of cyclooxygenase-2 (Cox-2) expression on a breast cancer tissue microarray.
  Zerkowski MP, RL Camp, BA Burtness, DL Rimm, and GG Chung., Cancer Invest; 25:19-26.
• Phase II Trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
  Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR., Cancer J 13:257-262.
• A randomized Phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of t...
  Burtness BA, Manola J, Axelrod R, et al., An Eastern CoopCooperative Oncology Group study. Annals Oncol 19:977-83.
• Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray.
  Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B., Cancer Epidemiol Biomarkers Prev; 17:1486-92.
• Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting.
  Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ, Am J Clin Oncol 33:599-603.
• Turaka A, Li T, Yu JQ, Nicolaou N, Burtness B, Lango MN, Ridge JA, Feigenberg SJ. Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer.
  Turaka A, Li T, Yu JQ, Nicolaou N, Burtness B, Lango MN, Ridge JA, Feigenberg SJ., Thyroid Sci 2010. 5:CLS1-5.
• Defining venous involvement in borderline resectable pancreatic cancer.
  Chun, YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Dushkin H, Astsaturov I, Kuritzky NK, Hoffman JP., Annals of Surg Oncol
• Initial results of a phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head and neck cancer.
  Rusthoven KE, Feigenberg, SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C., Int J Radiation Oncol Biol Phys
• Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis.
  Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A., Clin Cancer Res. 16:2427-34
• No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer.
  Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy..., Int J Radiat Oncol Biol Phys 79:65-70.
• Non-surgical management of oropharyngeal, laryngeal and hypopharyngeal cancer: the Fox Chase Cancer Center experience.
  Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA., Head and Neck; 33:1433-40.
• A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and...
  Argiris A, Ghebremichael M, Burtness B, Axelrod R, Deconti R, Forastiere AA., a trial of the Eastern Cooperative Oncology Group (E1303). Cancer; 117(15):3374-82.
• Comparative Prognostic Value of EGFR Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma (HNSCC).
  Pectasides E, Rampias T, Kountourakis P, Sasaki CT, Kowalski D, Fountzilas G, Zaramboukas T, Rimm DL, Burtness B, Psyrri A., Clin Cancer Res; 17(9):2947-54.
• Unilateral Neck Therapy in the Human Papillomavirus-Era: Virus Association does not Alter Accepted Regional Spread Patterns.
  Galloway T, Lango M, Burtness B, Mehra R, Ruth K, Ridge J., Head and Neck
• A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer.
  Dotan E, Meropol NJ, Burtness B, Denlinger C, Lee J, Mintzer D, Zambito F, Zhu F, Qi K, Tuttle H, Sylvester J, Astsaturov I, Cohen SJ., A Fox Chase Extramural Research Study. Journal of Gastrointestinal Cancer.
• Join now to see all

Lectures

• Debate: FLOT or Not—Revisiting the Current and Future Role of Radiotherapy in GE Junction Cancers 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
• Positive Rebuttal to Negative Position 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Setting Up and Running Multicenter Randomized Trials. 
  American Head and Neck Society Annual Meeting, Toronto.
• Integrating Targeted Therapies into Standard Treatments, Meet the Professor Session. 
  American Head and Neck Society Annual Meeting,Toronto.
• Esophagogastric Discussion: Trials in Unselected Patients, Gastrointestinal (Non-colorectal) Oral Abstract Session. 
  American Society of Clinical Oncology Annual Meeting, Chicago.
• PET and Head and Neck Cancer, Design of Comparative Effectiveness Research Studies of Molecular Imaging in Oncology: PET for Head and Neck Cancer. 
  Center for Medical Technology Policy, Baltimore
• Strategies for Overcoming Resistance to EGFR Inhibitors in Head and Neck Cancer. 
  City of Hope, Duarte CA
• Therapy of Locally Advanced Squamous Cell Cancer of the Head and Neck: State of the Art. Seventh Annual Multidisciplinary Symposium on Head and Neck. 
  Fox Chase Cancer Center/Physician’s Education Resource, Philadelphia.
• Biomarkers in Head and Neck Cancer. 
  NCCN Symposium on Respiratory Tract Cancers, Philadelphia.
• Entering the Era of Personalized Therapy in Head and Neck Cancer. 
  Physicians’ Education Resource Oncology Update, Philadelphia.
• Targeted Therapy Studies in ECOG. 
  American Head and Neck Society Research Workshop, Arlington
• Multidisciplinary Treatment of Head and Neck Cancer. 
  Oncology Grand Rounds, Walter Reed Medical Center, Washington, DC
• Implications of HPV Status for Clinical Trials Designs. 
  New York Head and Neck Society, New York.
• Molecular Markers to Personalize Head and Neck Cancer Therapy. 
  2nd Annual Meeting on Personalized Therapy in Lung Cancer and Head and Neck Cancer, Philadelphia
• Overcoming Resistance to EGFR Inhibitors in Head and Neck Cancer, Seminar Series 
  Section of Hematology-Oncology, University of Pennsylvania, Philadelphia.
• Biomarkers in Head and Neck Cancer. 
  Head and Neck Oral Presentation Session, Annual Meeting, American Society of Clinical Oncology
• EGFR Inhibition in Head and Neck Cancer, Cancer Center Seminar Series. 
  University of Illinois Chicago Circle Cancer Center
• Esophageal Cancer: New Agents and New Regimens. 
  Fox Chase Cancer Center Thoracic Oncology Symposium, Philadelphia
• Overcoming Resistance to EGFR Inhibitors in the Clinic. 
  Faculty Research Forum, Fox Chase Cancer Center, Philadelphia.
• Health Equity: Africa in the Era of HIV, Global Health Elective Lecture Series. 
  Temple University School of Medicine, Philadelphia
• HER: Can Resistance to EGFR Inhibitors be Overcome? Plenary Session, Molecular Targets: State of the Science 
  20th AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics Symposium, Geneva
• Abu Ghraib and the Failure of American Medical Education, The William and Wilma Haines/National Endowment for the Humanities Lecture in Bioethics. 
  The Center for the Humanities, Hood College, Frederick
• Abu Ghraib and the Failure of American Medical Education, The William and Wilma Haines/National Endowment for the Humanities Lecture in Bioethics. 
  The Center for the Humanities, Hood College, Frederick
• Trimodality Approach to Esophageal Cancer. 
  Yale University, Las Vegas
• Health Care Experiences in Tanzania. 
  International Health Organization, Temple University School of Medicine, Philadelphia.
• Join now to see all

Other

• "Liberia's only internist dies of Ebola: Remembering Abraham Borbor." 
  Burtness B, The Clinical Advisor
  1/1/2014
• Editor: "Current Cancer Research: Molecular Determinants of Head and Neck Cancer; Springer Verlag, New York" 
  Burtness B and Golemis E
  1/1/2013
• "Metastatic and Recurrent Head and Neck Cancer." (Updated Annually) 
  Tejani M and B Burtness, Clinical Care Options
  1/1/2010
• EGFR-targeted therapy in the treatment of squamous cell carcinoma of the head and neck. 
  Burtness BA and MS Kies, American Academy of CME, Inc.
  1/1/2004
• Editor, "Pancreatic Malignancies" 
  Burtness BA, www.emedicine.com
  1/1/2000
• "Cancer and Pregnancy; GN Burrow, editor" 
  Burtness BA
  1/1/2000
• "Gastric Cancer." 
  Aggarwal S and B Burtness, Physicians' Information and Education Resource (PIER), American College of Physicians
• Up-date Editor 2006-2007, "Gastric Cancer" 
  Burtness B, Physicians' Information and Education Resource (PIER), American College of Physicians
• Join now to see all